Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.11M | 12.41M | 15.17M | 13.89M | 15.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.11M | 12.41M | 15.17M | 13.89M | 15.14M |
| Cost of Revenue | 5.70M | 4.81M | 5.54M | 4.70M | 4.88M |
| Gross Profit | 10.41M | 7.60M | 9.62M | 9.19M | 10.25M |
| SG&A Expenses | 10.43M | 10.90M | 11.07M | 10.25M | 8.48M |
| Depreciation & Amortization | 761.00K | 761.00K | 526.00K | 444.00K | 921.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.88M | 16.48M | 17.14M | 15.39M | 14.50M |
| Operating Income | -777.00K | -4.06M | -1.97M | -1.50M | 640.00K |
| Income Before Tax | -4.00K | -5.61M | -10.58M | 1.97M | -19.44M |
| Income Tax Expenses | 11.00K | 10.00K | -- | -- | 437.00K |
| Earnings from Continuing Operations | -15.00K | -5.62M | -10.58M | 1.97M | -19.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 62.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.00K | -5.62M | -10.58M | 1.97M | -19.82M |
| EBIT | -777.00K | -4.06M | -1.97M | -1.50M | 640.00K |
| EBITDA | 344.00K | -2.94M | -1.09M | -701.00K | 2.10M |
| EPS Basic | 0.00 | -0.53 | -1.05 | 0.21 | -2.92 |
| Normalized Basic EPS | 0.00 | -0.33 | -0.66 | 0.13 | -1.03 |
| EPS Diluted | 0.00 | -0.53 | -1.05 | -0.08 | -2.92 |
| Normalized Diluted EPS | 0.00 | -0.33 | -0.66 | 0.06 | -1.03 |
| Average Basic Shares Outstanding | 19.32M | 10.51M | 10.04M | 9.44M | 6.79M |
| Average Diluted Shares Outstanding | 19.32M | 10.51M | 10.04M | 19.48M | 6.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |